Rearming the body’s immune system to fight cancer
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers
Pioneering excellence in the field of immunotherapy
Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.
Some of our partners
Latest news
Cartherics appoints new Chief Scientific Officer
By Christine Filippis / October 17, 2023
Melbourne, Australia, 17 October 2023 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More
Ovarian cancer is not ovarian cancer
By Christine Filippis / October 3, 2023
Cartherics’ Dr Ian Nisbet (Chief Operating Officer) and Kathy Skoff (Clinical Trials Manager) recently attended an ovarian cancer symposium in...
Read More
Combining new and existing immunity: a 3D approach to killing cancer
By Christine Filippis / September 25, 2023
by Richard Boyd and Aleta Pupovac A question which has long baffled scientists, frustrated clinicians and devastated patients is why...
Read More
